The REDEFINE-1 trial results were positive but did not meet the expectations set by the company and market, leading to a decline in Novo Nordisk's share price. The flexible dosing protocol was a key factor in the underwhelming results, as it resulted in fewer patients reaching the highest dose, thus impacting the overall efficacy.